fluoxetine has been researched along with Multiple System Atrophy in 1 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Multiple System Atrophy: A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)
| Excerpt | Relevance | Reference |
|---|---|---|
| "There are no effective treatments for multiple system atrophy (MSA)." | 7.01 | Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. ( Azulay, JP; Cochen de Cock, V; Corvol, JC; Couratier, P; Damier, P; Defebvre, L; Durif, F; Fabbri, M; Foubert-Samier, A; Geny, C; Houeto, JL; Meissner, WG; Pavy-Le Traon, A; Perez-Lloret, S; Rascol, O; Remy, P; Rousseau, V; Sommet, A; Thalamas, C; Tison, F; Tranchant, C; Verin, M, 2021) |
| "There are no effective treatments for multiple system atrophy (MSA)." | 3.01 | Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. ( Azulay, JP; Cochen de Cock, V; Corvol, JC; Couratier, P; Damier, P; Defebvre, L; Durif, F; Fabbri, M; Foubert-Samier, A; Geny, C; Houeto, JL; Meissner, WG; Pavy-Le Traon, A; Perez-Lloret, S; Rascol, O; Remy, P; Rousseau, V; Sommet, A; Thalamas, C; Tison, F; Tranchant, C; Verin, M, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rascol, O | 1 |
| Cochen de Cock, V | 1 |
| Pavy-Le Traon, A | 1 |
| Foubert-Samier, A | 1 |
| Thalamas, C | 1 |
| Sommet, A | 1 |
| Rousseau, V | 1 |
| Perez-Lloret, S | 1 |
| Fabbri, M | 1 |
| Azulay, JP | 1 |
| Corvol, JC | 1 |
| Couratier, P | 1 |
| Damier, P | 1 |
| Defebvre, L | 1 |
| Durif, F | 1 |
| Geny, C | 1 |
| Houeto, JL | 1 |
| Remy, P | 1 |
| Tranchant, C | 1 |
| Verin, M | 1 |
| Tison, F | 1 |
| Meissner, WG | 1 |
1 trial available for fluoxetine and Multiple System Atrophy
| Article | Year |
|---|---|
Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial.
Topics: Double-Blind Method; Fluoxetine; Humans; Multiple System Atrophy; Parkinson Disease; Quality of Life | 2021 |